Controversies in multiple myeloma: Evidence-based update

Slides:

Advertisements

Similar presentations

Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria MULTIPLE MYELOMA.

Advertisements

Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients Palumbo A.

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.

Treatment of early-stage Hodgkin lymphoma

From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.

Volume 144, Issue 1, Pages (January 2017)

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis Anthony T. Reder, Joel F. Oger, Ludwig Kappos, Paul O’Connor,

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Lucky Jain, MD, MBA Clinics in Perinatology

Evaluation of Proteinuria

Y. Hicheri, G. Cook, C. Cordonnier Clinical Microbiology and Infection

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Obsessive Compulsive Disorder: A Clinical Update

Volume 15, Issue 8, Pages (July 2014)

George Dailey, MD Mayo Clinic Proceedings

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Y. Hicheri, G. Cook, C. Cordonnier Clinical Microbiology and Infection

Volume 146, Issue 3, Pages (September 2017)

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Dan T. Vogl, Tao Wang, Waleska S. Pérez,

A Guide to Exercise Prescription

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Stem Cell Therapies in Clinical Trials: Progress and Challenges

Human epidermal growth factor receptor 2 borderline mortality in breast cancer patients: Evidence from surveillance, epidemiology, and end results program.

Sumit Madan, MD, Robert A. Kyle, MD, Philip R. Greipp, MD

Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow.

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Efficacy and Toxicity of Idarubicin Versus High-dose Daunorubicin for Induction Chemotherapy in Adult Acute Myeloid Leukemia: A Systematic Review and.

Targeting T Cell Co-receptors for Cancer Therapy

Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review Rahul Mhaskar,

Jacques Irani European Urology Supplements

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review Denise M.

The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis P.C. Minneci, K.J. Deans, P.Q. Eichacker, C. Natanson

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Volume 63, Issue 3, Pages (March 2003)

Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous.

Long-Term Hormonal Therapy: Who Would Benefit?

Sergio Bracarda European Urology Supplements

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Axel Heidenreich European Urology Supplements

U.S. Hospice Benefits Journal of Pain and Symptom Management

Volume 143, Issue 6, (December 2010)

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Volume 373, Issue 9672, Pages (April 2009)

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition Terry M. Therneau, PhD,

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda,

Oncoforum Urology: Prostate Cancer 2008 at a Glance

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review Theresa Hahn,

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis.

Guy S. Reeder, M.D., Raymond J. Gibbons, M.D. Mayo Clinic Proceedings

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Hematopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders Martin Benesch, MD, H. Joachim.

Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.

Autologous Stem Cell Transplantation for POEMS Syndrome

Human epidermal growth factor receptor 2 borderline mortality in breast cancer patients: Evidence from surveillance, epidemiology, and end results program.

Presentation transcript:

Controversies in multiple myeloma: Evidence-based update Inhye E. Ahn, Sham Mailankody Seminars in Oncology Volume 43, Issue 6, Pages 666-675 (December 2016) DOI: 10.1053/j.seminoncol.2016.10.006 Copyright © 2016 Elsevier. Terms and Conditions

Fig. 1 Probability of progression to active multiple myeloma or primary amyloidosis in patients with smoldering multiple myeloma or monoclonal gammopathy of undetermined significance. Adapted from Kyle et al [1]. Seminars in Oncology 2016 43, 666-675DOI: (10.1053/j.seminoncol.2016.10.006) Copyright © 2016 Elsevier. Terms and Conditions

Fig. 2 Discrepancy between Mayo clinic and Spanish risk stratification models in smoldering multiple myeloma. Adapted with permission [6]. Seminars in Oncology 2016 43, 666-675DOI: (10.1053/j.seminoncol.2016.10.006) Copyright © 2016 Elsevier. Terms and Conditions

Fig. 3 Comparison of upfront high-dose therpy and single autologous stem cell transplant (HDT) and nonmyeloablative standard-dose therapy (SDT). (A) Forest plot of overall survival comparing benefit of HDT and SDT. (B) Assessment of potential harm with upfront HDT. The table presents the anticipated transplant-related mortality (TRM) with upfront HDT (based on threefold increased odds of death with HDT versus SDT), for a range of possible TRM rates in the SDT arm. Based on these estimates, the number of patients that need to be enrolled to the HDT arm to have oneexcess HDT toxicity-related death (v those in the SDT arm) is also indicated, as is the number of such excess deaths anticipated per 1,000 patients enrolled to upfront HDT. Adapted with permission [32]. Seminars in Oncology 2016 43, 666-675DOI: (10.1053/j.seminoncol.2016.10.006) Copyright © 2016 Elsevier. Terms and Conditions